Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elderly untreated CLL trial of fludarabine, cyclophosphamide, and rituximab
ACTRN12608000404325Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Proportion of patients completing 6 treatment cycles. Started Dec 2008; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12608000404325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000404325.